On July 8, Tempus AI fell 5.09% in pre-market trading, trading at $57.03/share, with turnover of approximately $1.53 million. The decline was triggered by Biovica International AB announcing the termination of its collaboration agreement with Tempus AI.

According to the announcement, Biovica stated that the partnership with Tempus AI failed to result in any product commercialization or generate any revenue, prompting the company to realign its U.S. commercial strategy. Biovica noted that the termination would not affect its San Diego laboratory, U.S. clinical activities, or its pharmaceutical services business. The strategic adjustment aims to more effectively advance its core business in the U.S. market.

Separately, Tempus AI CEO and Chairman Eric P. Lefkofsky sold approximately 126,250 shares of Class A common stock on June 29 through a pre-arranged Rule 10b5-1 trading plan at prices ranging from $54.82 to $59.59 per share. Tempus AI is a healthcare technology company that leverages artificial intelligence to connect laboratory results with clinical data to enable more intelligent and personalized diagnostic testing.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)